Institutional members access full text with Ovid®

Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK

Fox, Juliea,c; Castro, Hannahb,c; Kaye, Stevea; McClure, Myraa; Weber, Jonathan Na; Fidler, Saraha; on behalf of the UK Collaborative Group on HIV Drug Resistance

doi: 10.1097/QAD.0b013e32833cbb5b
Epidemiology and Social: CONCISE COMMUNICATION

Objectives: To describe the frequency and risk factors of non-B HIV-1 subtypes in men who have sex with men (MSM) in the UK.

Design: Observational study.

Methods: MSM diagnosed with HIV-1 infection from 1980–2007, with HIV genotype held in the UK HIV Drug Resistance Database were identified. Protease and reverse transcriptase sequences were collected and viral clade determined using the REGA algorithm. Associations between demographic variables and subtype were analysed using logistic regression.

Results: The prevalence of non-B HIV-1 infection amongst MSM in the UK was 5.4% (437/8058). In the UK this increased with year of diagnosis from pre1996 to 2002, and has subsequently remained relatively stable at around 7–9% after 2002, with a recent increase in 2007 to 13%. Multivariate analysis showed that acquisition of non-B HIV-1 infection was independently associated with later year of HIV diagnosis (P < 0.001), black ethnicity (P < 0.001) and non-European country of birth (P = 0.01). Age was also associated with subtype with individuals aged 25–39 years being less likely to have non-B virus than those aged less than 25 years (P = 0.01). Restricting the analysis to white men born in the UK, the association between subtype and year of diagnosis remained statistically significant (P < 0.001), as did the association with age (P < 0.001).

Discussion: The number of MSM in the UK infected with non-B clade HIV-1 is increasing, suggesting that the sociodemographic boundaries between HIV-1 viral subtypes globally are diminishing. Should viral subtypes be relevant to clinical disease progression or vaccine design, the changing pattern of distribution will need to be taken into account.

aDepartment of HIV, Guys and St Thomas' NHS Trust, UK

bDepartment of Genitourinary Medicine and Infectious Disease, Division of Medicine, Wright Fleming Institute, Imperial College, UK

cHIV Group, Medical Research Council Clinical Trials Unit, London, UK.

Received 9 February, 2010

Revised 26 May, 2010

Accepted 2 June, 2010

Correspondence to Dr Julie Fox, Consultant HIV, Guys and St Thomas' NHS Trust/ Kings College London, Harrison Wing, St Thomas' Hospital, Westminster Bridge Road, London, UK. Tel: +44 7971095949; e-mail: julie.fox@kcl.ac.uk

© 2010 Lippincott Williams & Wilkins, Inc.